Carregant...
A systematic review of the budget impact analyses for antitumor drugs of lung cancer
BACKGROUND: Budget impact analyses (BIAs) are used for reimbursement decisions and drug access medical insurance, as a supplement to cost-effectiveness analyses (CEAs). OBJECTIVES: We systematically reviewed BIAs for antitumor drugs of lung cancer to provide reference for high-value drug budget impa...
Guardat en:
| Publicat a: | Cost Eff Resour Alloc |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7706257/ https://ncbi.nlm.nih.gov/pubmed/33292288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-020-00253-5 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|